Kotobuki Pharmaceutical

Sakaki-machi, Nagano, Japan· Est. 1949

A Japanese pharmaceutical company focused on manufacturing and developing small molecule drugs in gastroenterology, oncology, and neurology, with expertise in formulation development.

kotobuki-pharm.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese pharmaceutical company focused on manufacturing and developing small molecule drugs in gastroenterology, oncology, and neurology, with expertise in formulation development.

OncologyGastroenterologyNeurologyMetabolic DiseasePain

Technology Platform

Focus on pharmaceutical formulation development, with specialized expertise in creating patient-friendly orally disintegrating (OD) tablets designed for water-free administration.

Opportunities

Growth opportunities include expanding the market for its formulation-advanced products (OD tablets), lifecycle management and geographic expansion (e.g., China) for key assets like gilteritinib, and leveraging its Medical Science Office to build stronger clinical evidence for its portfolio.

Risk Factors

Key risks include reliance on a partnered blockbuster asset (gilteritinib), competition in crowded therapeutic areas like gastroenterology and diabetes, and the challenges of a smaller company in funding broad R&D initiatives against larger pharmaceutical competitors.

Competitive Landscape

Competes with large Japanese pharma (Takeda, Astellas) and global generics/specialty pharma companies in its core areas; differentiation is achieved through specialized formulation technology (OD tablets) and established brand loyalty for products like MARZULENE.

More companies in Japan →